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Clinical Review of Epidemic Kaposi's Sarcoma with Focus on 
Treatment Modalities 
Judie Goodman, DO,* Robert Chapman, MD,^  and Eyal Meiri, MD^ 
Kaposi's sarcoma, once a rare neoplasm, is now a common malignant disorder in persons with the acquired immu-
nodeficiency syndrome (AIDS). Kaposi's sarcoma was origi-
nally described in 1872 by Moriz Kaposi, a Hungarian physi-
cian. Before the development of AIDS, Kaposi's sarcoma was a 
rare tumor seen in three distinct populations: 1) elderly men of 
Italian or eastern European Jewish origin, 2) Africans, and 
3) patients with immunologic disorders. In the first group, the 
tumor (classic Kaposi's sarcoma) mns an indolent course. An 
endemic form of Kaposi's sarcoma is seen in the African pop-
ulation, where both adults and prepubescenl children may 
be affected. The presentation of the disease in these patients 
is varied; it may be indolent in some adults, locally invasive 
and aggressive in young adults, or may present as a lymph-
adenopathic form seen in prepubescenl children with general-
ized nodal and visceral involvement and a very poor prognosis. 
The third group includes patients with some type of immun-
ologic disorder: renal transplant recipients on immunosup-
pressive therapy, patients with primary immunodeficiency 
disorders, or patients with lymphoproliferalive diseases. The tu-
mor may be localized or widely disseminated in these patients 
(1-4), Together, these three groups of patients have a 10% inci-
dence of organ involvement. The heart is most commonly 
involved (67%), followed by lymph nodes (53%), and the 
gastrointestinal tract (45%) (5), 
Clinical Aspects of Epidemic Kaposi's Sarcoma 
Since the recognition of AIDS in 1981, the once rare Kaposi's 
sarcoma (< 2% of all sarcomas) is now a commonplace neo-
plasm. Epidemic Kaposi's sarcoma (EKS), as referred to in 
AIDS patients, is not seen with equal frequency in all high-risk 
groups. The overall incidence of EKS in association with AIDS 
is approximately 30% (4), but ranges from 46% to 48% in 
homosexual men, 4% in heterosexual intravenous drug abusers, 
and 12% in Haitian AIDS patients (1,3,4). 
The increased incidence of EKS in homosexual men, as op-
posed to other high-risk groups, suggests that these patients may 
be exposed to additional factors which enhance the development 
of the neoplasm. One such factor is the cytomegalovirus 
(CMV). Studies have shown serologic evidence of CMV infec-
tions in endemic African Kaposi's sarcoma (2) and in classic 
Kaposi's sarcoma (6). However, due to the ubiquity of CMV in 
homosexual men (1), the actual significance of the vims in the 
etiology of the neoplasm is not yet clean 
The histologic characteristics of Kaposi's sarcoma are identi-
cal in all population groups (1), The two essential features 
necessary for diagnosis include: 1) vascular proliferation, and 
2) spindle-shaped neoplastic cells embedded in reticulin fibers 
(5), The neoplastic cell appears to be of vascular endothelial ori-
gin, based on immunohistochemical studies (7) and electron 
microscopy (8,9). The tumor also appears to be multifocal and 
systemic at the onset, without the usual characteristics of a 
metastasizing neoplasm, ie, locally advancing, lymphatic, or 
hematogenous spread (1,2,4), A hypothesis is that profound 
cell-mediated immune depression in AIDS patients, which vir-
tually destroys T-cell mediated immune surveillance, may be 
combined with a specific tumor growth factor which allows for 
rapid, uninhibited neoplastic vascular proliferation locally or in 
distant foci. Hence, EKS may be regarded as an opportunistic 
neoplasm (10), 
Four clinical subtypes have been described in the endemic 
African Kaposi's sarcoma. The nodular subtype is characterized 
by the presence of skin nodules and a relatively indolent course. 
The florid and infiltrative forms are associated with locally ag-
gressive tumors and bone involvement. The lymphadenopathic 
form is usually disseminated, involving lymph nodes and 
visceral organs (11), EKS resembles both the nodular and 
lymphadenopathic subtypes (2), 
EKS lesions are generally asymptomatic. They may appear 
initially as pink, red, or violet, flat macules distributed in 
localized clusters or with wide dissemination (1,4,10). As the 
lesions progress, they become elevated (plaque stage) and 
finally may coalesce and become nodules (nodular stage). 
A staging system for EKS, initially proposed by Krigel et al 
(12), is summarized in Table I . This staging system includes all 
the variants of Kaposi's sarcoma. Each stage is further sub-
divided into "A" or "B" subtypes, depending on the presence or 
absence of fever (unrelated to an infectious source) or weight 
loss (greater than 10%). 
Several important observations may be drawn from the initial 
longitudinal analysis of the patient population. First, sites of dis-
ease are variable. In 61 % of patients, lymphadenopathy was gen-
eralized at initial presentation. The skin lesion manifestations 
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Table 1 
Clinical Staging of Kaposi's Sarcoma 
Stage I Cutaneous, locally indolent 
Stage II Cutaneous, locally aggressive with or without regional lymph 
nodes 
Stage I I I * Generalized mucocutaneous and/or lymph node involvement 
Stage IV Visceral 
Subtype A No systemic signs or symptoms 
Subtype B Systemic signs: 10% weight loss or fever greater than 100°F 
orally and unrelated to an identifiable source of infection 
lasting more than two weeks 
'Generalized: more than upper or lower extremities alone; includes minimal gastroin-
testinal disease defined as more than five lesions and greater than 2 cm in combined 
diameters. 
ranged from none in 8% to generalized in 63%, while only one 
patient had a locally exophytic lesion. Survival is definitely 
related to the presence or absence of opportunistic infection 
(13), Patients who present with EKS but without an oppor-
tunistic infection have a better survival rate than those with an 
opportunistic infection (80% versus 15% alive at 30 months). Pa-
tients with "B" symptoms or opportunistic infections do poorly 
regardless of the stage of infection. 
The New York University (NYU) staging system has definite 
prognostic value (14-16). All patients are subdivided into three 
groups: I) the good prognosis group (stage 1), with 100% sur-
vival at 18 months; 2) the intermediate prognosis group (stages 
Ill-A and IV-A), with 85% survival at 18 months; and 3) the poor 
prognosis group (stages III-B, IV-B, and coexistent oppor-
tunistic infections), with 24% survival at 18 months. 
While clinical parameters appear to be prognostically useful, 
laboratory data are also important. The leukocyte and absolute 
lymphocyte counts in AIDS patients with EKS are closely asso-
ciated with survival (4). The T-helper/T-suppressor cell ratio and 
the absolute level of T4 positive T-cells are also excellent predic-
tors of survival (5). Patients with 30% or more T4 (helper) cells 
survived longer than those with less than 30% T4 cells (68% 
versus 44% were alive two years after diagnosis). Patients with 
T4/T8 (suppressor) ratios of at least 1.7 survived longer than 
those with either a ratio between 1.0 and 1.6 or less than 1.0. 
Specifically, the proportion of patients alive two years after di-
agnosis are 93%, 64%, and 43%, respectively (4). In general, as 
epidemic Kaposi's sarcoma progresses, a progressive decrease 
occurs in the T4/T8 ratio and the absolute T4 number A recent 
analysis of prognostic variables in EKS showed laboratory pa-
rameters to be more important in predicting survival than 
clinical parameters (17). The presence or absence of endogenous 
interferon coupled with the hematocrit correlated with survival. 
The best risk group (group I) had absent endogenous interferon 
with a hematocrit greater than 38.8 and a median survival of 
41.34 ± 6.36 months. In contrast, the poorestrisk group (group 
IV) had endogenous interferon present with a hematocrit less 
than 38.8 and a median survival of 10.55 ± 0,96 months. 
Therapy 
The treatment of epidemic Kaposi's sarcoma was initially 
guided by recommendations given at a 1981 National Cancer In-
stitute workshop, where i l was suggested that I) patients with 
Table 2 
Chemotherapy Trials in Epidemic Kaposi's Sarcoma 
Percent of 
N o . o f Objective Percent of Percent of 
Drug Patients Response CR* PRt 
VP-16 (19)11 41 76 30 46 
Vinblastine (20) 38 26 2 23 
Vincristine (21) IX 61 0 61 
ABV (19)* 31 84 23 61 
ABV(22)t 9 77 11 66 
Bleo-VP-16 (23) 7 IOO 57 43 
Vinblastine/MTX (24)§ 9 77 33 44 
Vinblastine/Bleo (25) 31 0 62 
Vinblastine/Vincristine (26) 20 45 5 40 
*CR - complete response; total regression of ail signs of tumor 
tPR = partial response: greater than 50% regression of each tumor lesion. 
tAdriamycin, bleomycin, and vinblastine. 
?!Methotrcxate. 
IIFtoposide. 
limited disease receive local treatment, ie, radiation; 2) patients 
with widespread but slowly progressive disease be treated with 
single agent therapy; and 3) patients with advanced and rapidly 
progressive disease be treated with combination chemotherapy 
(18). However, some difficulties are encountered in evaluating 
treatment modalities of EKS. Because AIDS is a relatively re-
cent phenomenon, the natural history of EKS has not been well 
defined; hence the natural progression of the disease versus that 
caused by manipulation of treatment regimens is hard to assess. 
While the NYU staging system is used by some investigators, it 
is not universally accepted (4,18). Therefore, meaningful eval-
uation of various treatment regimens is difficult. 
The single agents most widely used are the vinca alkaloids 
and the epidophyllotoxin etoposide. Several recent trials are 
summarized in Table 2 (19-26). 
At Henry Ford Hospital, 31 patients have been diagnosed as 
having epidemic Kaposi's sarcoma. Their treatment has been 
quite variable, including combinations with the vinca alkaloids, 
vinblasdne, vincristine, bleomycin, and VP-16. The median 
survival of these 31 patients has been 11 months from their diag-
nosis of AIDS. Seven of the 31 patients have died as a result of 
Kaposi's sarcoma. Eight other patients died of opportunistic 
infections. The remaining 16 patients are still alive. 
Because opportunistic infections are a major problem in EKS 
patients on combination chemotherapy, several investigators 
have developed protocols that are less myelosuppressive. Wemz 
et al (25) treated 31 patients with alternating weekly doses of vin-
blastine and bleomycin. Many patients had "B" symptoms (as 
defined in Table 1), prior opportunistic infections, or received 
prior treatment. Fifteen patients developed their first oppor-
tunistic infection while on treatment. Twenty-four patients 
achieved a partial response (7), four had stable disease, and two 
had no response. 
Chemotherapy given as eilher a single agent or in combina-
tion is effective as palliative therapy in many patients with EKS 
(Table 2), Because our knowledge of the natural history of this 
disease is limited, it is unclear whether the administration of 
chemotherapy confers any survival advantage. Clearly, the un-
deriying immune defect and subsequent opportunistic infection 
remain a major problem in these patients. 
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Table 3 
Interferon Trials in Epidemic Kaposi's Sarcoma 
Percent of 
No. of Objective Percent of Percent of 
interferon Dose Patients Response CR* PRt 
Recombinant Interferon 36 to 54 X 106 U/day intra- 36 38 23 15 
Alpha (28) muscularly (IM) 4 to 8 weeks 
3 X lOoU/day 39 3 0 3 
IM 4 to 8 weeks 
(No response, escalate to higher 33 17 10 7 
dose) 
Recombinant Interferon I X 10' U/m-/day subcutaneously; 10 20 
— — 
Alpha(29) altemate weeks for 8 weeks if no re-
sponse 
Escalate to 50 x lO"-U/m /^day intra- 10 4.0 
— — 
venously; alternate weeks for 8 weeks 
50 X 10*'U/m-/day intravenously; al- 20 32 
— — 
temate weeks for 8 weeks 
30 X 10'U/m^/day subcutaneously 64 31 
— — 
for 8 weeks 
Human Lymphoblastoid 7.5 X lO'U/m^ 9 11 0 11.1 
Interferon (30) IM daily for 28 days 
15 X I06U/m2 10 0 0 0 
IM daily for 28 days 
25 X lO'U/m^ 10 30 30 0 
IM daily for 28 days 
Overall response 29 13 10 3 
Human Lymphoblastoid 20 X lO'U/m^ 12 67 33.3 33.3 
Interferon (31) IM for 28 days or 2 months 
'CK = complete response: total i 
tPR = partial response: greater t 
n of all signs of tumor 
regression of each tumor lesion. 
The natural properties of interferon make its use appealing in 
epidemic Kaposi's sarcoma. Specifically, interferon has known 
antiproliferative, antiviral, and immunomodulatory effects 
(27). Investigators have hoped that the antiproliferative proper-
ties might combat the rapidly progressive EKS. The antiviral 
effects of interferon might combat the underlying causative 
agent of AIDS or other clinically important viral infections, and 
perhaps the immunomodulatory effects of interferon might 
improve the underlying immune defect in these patients. 
Most interferon investigations in EKS have used either 
recombinant interferon alpha or lymphoblastoid interferon. 
Real et al from the Memorial Sloan-Kettering Cancer Center 
(MSKCC) studied the use of both low and high doses of recom-
binant leukocyte a interferon in 75 patients (28). Patients were 
staged according to a MSKCC staging system and excluded if 
there was an ongoing infection or previous treatment with re-
combinant interferon. The doses and results are depicted in 
Table 3, along with three other interferon trials. In this study a 
positive correlation occurred between response to interferon 
treatment and a history of previous opportunistic infection, but 
no association was found with tumor burden or visceral involve-
ment. In addition, a highly significant survival difference was 
observed in respohders versus nonresponders. 
Volberding and Mitsuyasu (29) evaluated several dose levels 
of recombinant alpha interferon (Table 3). Clinically poor prog-
nostic factors, ie, "B" symptoms and opportunistic infection, 
affected response to therapy. Human lymphoblastoid interferon 
was studied in several dose ranges at the National Cancer 
Institute (30). Interestingly, all patients receiving the highest 
dose level required a 75% dose reduction due to toxicity, so that 
all patients received between 6 and 15 x 10* U/m- daily by the 
second week of therapy. In this study, patients with no history of 
opportunistic infections or chronic CMV viremia and with 
higher total lymphocyte counts and absolute T4 counts had a 
better chance at a response. 
Clearly, recombinant interferon and human lymphoblastoid 
interferon are active in treating patients with epidemic Kaposi's 
sarcoma. Several factors seem to enhance response rates: the 
lack of "B" symptoms (29), the absence of opportunistic infec-
fions (28-30), and the lack of endogenous acid-labile alpha inter-
feron (29-32). While tumor burden was an important prognostic 
variable in one study (31), it had no effect in another (28). Simi-
larly, while some immunologic parameters correlated with re-
sponse in one study (30), this has not been a universal finding 
(32). The actual mechanism whereby interferon induces tumor 
regression is unknown. 
Many questions regarding the natural history and treatment of 
epidemic Kaposi's sarcoma remain unanswered. While chemo-
therapy and interferon treatments are active treatments for the 
disease, a true long-term survival benefit has not been docu-
mented. Persistent observation and study, including prospec-
tively randomized therapy trials, are essential to continue the 
progress against this disease. 
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